·1 хв читання · 38 слів·👁 8.1K↗ 12
Singapore’s KPB Biosciences fails in bid to unfreeze assets in US$830 million Novo Nordisk legal battle
The Danish drugmaker alleges that KPB misled it about its drug for hypertension and kidney disease, which has since been proven ineffective.



